Anti-Mouse ICAM-1 (CD54) (Clone BE29G1) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse ICAM-1 (CD54) (Clone BE29G1) – Purified in vivo GOLD™ Functional Grade
Product No.: C391
Clone BE29G1 Target Inter-Cellular Adhesion Molecule 1 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names BB2, CD54, P3.58 Isotype Rat IgG2a Applications B , in vivo , IP , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified Recombinant Mouse ICAM-1 (>98%) Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737487 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Rat Anti-Mouse CD54 (Clone BE29G1) recognizes the (Mr 95 kD) cell surface glycoprotein known as intracellular adhesion molecule ICAM-1. ICAM-1 is the receptor for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18).1,2,3 Background Intercellular adhesion molecule-1 (ICAM-1) is one of an important cell adhesion molecules (CAMs) family transmembrane glycoprotein1 and is critical for the firm arrest and transmigration of leukocytes out of blood vessels and into tissues. ICAM-1 is constitutively present on endothelial cells, but its expression is increased by proinflammatory cytokines.2 ICAM-1 is a marker of endothelial dysfunction leading to damaging vascular disorders, in umbilical and placental vascular tissue of gestational pregnancies.3 Antigen Distribution The CD54 antigen is present on endothelial cells, lymphocytes, epithelial cells, dendritic cells and keratinocytes. It has been demonstrated that ICAM-1 enhances T-cell activation.
Ligand/Receptor CD11a/CD18 (LFA-1) or CD11b/CD18 (Mac-1) and CD11c/CD18, CD43, hyaluronan, fibrinogen NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Cell Biology . Costimulatory Molecules . Immunology . Innate Immunity . Neuroscience . Neuroscience Cell Markers . Stem Cell Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone BE29G1 is a monoclonal antibody specific for mouse intercellular adhesion molecule 1 (ICAM-1), and it is used in in vivo mouse studies primarily to functionally block or deplete ICAM-1 in the context of immune and cancer research. Essential supporting details:
For example, one experimental setup described the injection of mice with tumor cells, then administration of blocking/depleting antibodies (including anti-ICAM-1) to study their effects on tumor progression or the infiltration of immune cells. Product availability: BE29G1 for in vivo use is available in low-endotoxin, research-grade formulations suitable for injection into mice, ensuring minimal adverse reactions due to contaminants. No other use or modifications (e.g., reporter or knockout models) for BE29G1 itself are described in the search results; its primary in vivo application is the functional blockade of ICAM-1 in mouse studies. Some of the most commonly used antibodies or proteins studied alongside BE29G1 (a V2 apex broadly neutralizing antibody, bnAb) in the HIV-1 antibody literature include other V2 apex bnAbs, V3-glycan bnAbs, and epitope-specific control antibodies. Common antibodies/proteins used in these studies include:
These antibodies are often used in combination for:
In summary, BE29G1 is frequently studied in panels alongside key V2 apex antibodies (like PG9, PG16, PGT145), glycan-dependent and interface-targeting bnAbs (e.g., PGT128, 2G12, PGT151), and appropriate control antibodies such as DEN3. All these support robust experimental controls and provide comparative context for BE29G1 activity and specificity in the literature. Clone BE29G1 is a monoclonal antibody specific for mouse intercellular adhesion molecule 1 (ICAM-1), widely used in immunological research involving mouse models. The most significant findings from scientific literature citing clone BE29G1 include:
While literature provides robust evidence supporting BE29G1s utility for detecting ICAM-1, there are no major conflicting findings regarding its specificity or reliability. Its continued citation in papers underscores its status as a standard reagent in murine immunology. No evidence from search results suggests non-standard or problematic findings associated with clone BE29G1; it is used reliably for detecting murine ICAM-1 in immunological research contexts. There is no publicly available data in the provided search results specifying dose regimens for clone BE29G1 in mouse models. No dosing schedules, recommended amounts, or strain-dependent adjustments are described for clone BE29G1 specifically. The available dosing guides and published studies reference other antibody clones (such as RMP1-14, 10F.9G2, and 29F.1A12), detailing their recommended doses, administration frequency, routes, and differences across mouse models, but do not address BE29G1. If you have data on BE29G1’s molecular target or its intended use, guidance may be inferred from similar clones aimed at the same target, typically adjusting for:
Without direct dosing information for clone BE29G1, it is standard practice to pilot with doses consistent with well-characterized antibody clones and then empirically adjust for efficacy and tolerability in your specific mouse model. Should you need dosing regimens for a well-studied antibody clone, refer to the detailed in vivo dosing guides that match your target and application. For BE29G1, consult original manufacturer protocols or peer-reviewed primary literature for definitive dosing recommendations. References & Citations1. Li S et al. (2009) Biochem Biophys Res Commun. 381: 459
2. Wolf S et al. (2009) Pharmacol Rep 61: 22 3. Ozcan U et al. (2009) Arch Gynecol Obstet. Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-1177 | |
C247 | |
F1175 | |
R1214 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
C1764 | |
C1767 | |
C267 | |
C354 | |
C268 | |
C1759 | |
C1760 | |
C1761 | |
C1763 | |
C269 | |
C270 | |
C391 | |
C991 |
